Mereo Biopharma Group Plc ADR’s recently made public that its Chief Executive Officer Scots-Knight Denise unloaded Company’s shares for reported $0.25 million on Sep 13 ’24. In the deal valued at $4.22 per share,60,046 shares were sold. As a result of this transaction, Scots-Knight Denise now holds 808,921 shares worth roughly $2.02 million.
Then, Scots-Knight Denise sold 28,611 shares, generating $127,968 in total proceeds. Upon selling the shares at $4.47, the Chief Executive Officer now owns 868,967 shares.
Before that, Lewicki John A. sold 10,937 shares. Mereo Biopharma Group Plc ADR shares valued at $46,165 were divested by the Chief Scientific Officer at a price of $4.22 per share. As a result of the transaction, Lewicki John A. now holds 78,630 shares, worth roughly $0.2 million.
JP Morgan initiated its Mereo Biopharma Group Plc ADR [MREO] rating to an Overweight in a research note published on March 27, 2025; the price target was $7. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Robert W. Baird began covering MREO with “an Outperform” recommendation on June 13, 2024.
Price Performance Review of MREO
On Monday, Mereo Biopharma Group Plc ADR [NASDAQ:MREO] saw its stock jump 3.73% to $2.50. Over the last five days, the stock has lost -1.96%. Mereo Biopharma Group Plc ADR shares have fallen nearly -28.57% since the year began. Nevertheless, the stocks have fallen -19.35% over the past one year.
Levels Of Support And Resistance For MREO Stock
The 24-hour chart illustrates a support level at 2.43, which if violated will result in even more drops to 2.36. On the upside, there is a resistance level at 2.56. A further resistance level may holdings at 2.62. The Relative Strength Index (RSI) on the 14-day chart is 54.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.07, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 53.19%. Stochastics %K at 35.73% indicates the stock is a holding.
The most recent change occurred on August 12, 2022 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $4 price target.
